The Best Practices for Screening, Monitoring, and Diagnosis of Cytomegalovirus Disease, Part I

Clinical Microbiology Newsletter

Volumn 32, Issue 1, 2010, Pages 1-6

  Lazzarotto, Tiziana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTOMEGALOVIRUS ANTIGEN PP65; GANCICLOVIR; VALGANCICLOVIR; VIRUS DNA;

ANTIVIRAL THERAPY; ARTICLE; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL MONITORING; INFECTION PREVENTION; LABORATORY DIAGNOSIS; NEPHROTOXICITY; NONHUMAN; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; VIREMIA; VIRUS DETECTION; VIRUS REPLICATION;

EID: 72149084168     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinmicnews.2009.12.001     Document Type: Article

References (13)

1. Mocarski E.S., Shenk T., and Pass R.F. Cytomegalovirus. In: Knipe D.M., and Howley P.M. (Eds). Fields virology. 5th ed. (2007), Lippincott Williams and Wilkins, Philadelphia, PA 2701-2772
2. Landolfo S., et al. The human cytomegalovirus. Pharmacol. Ther. 98 (2003) 269-297
3. Fishman J.A. Infection in solid-organ transplant recipients. N. Engl. J. Med. 357 (2007) 2601-2614
4. Razonable R.R., and Emery V.C. Management of CMV infection and disease in transplant patients. Herpes 11 (2004) 77-86
5. Gerna G., and Lilleri D. Monitoring transplant patients for human cytomegalovirus: diagnostic update. Herpes 4 (2006) 11-13
6. Lilleri D., et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol. 32 (2009) 245-253
7. Pang X.L., et al. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 9 (2009) 258-268
8. Caliendo A.M., et al. A commutable cytomegalovirus calibrator is required to improve the agreement of viral load values between laboratories. Clin. Chem. 55:1701-1710.
9. Razonable R.R., et al. The clinical use of various blood compartments for cytomegalovirus (CMV) DNA quantitation in transplant recipients with CMV disease. Transplantation 73 (2002) 968-973
10. Snydman D.R. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplant: the case for prophylaxis. Clin. Infect. Dis. 40 (2005) 709-712
11. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin. Infect. Dis. 40 (2005) 704-708
12. Gerna G., et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant 6 (2006) 2356-2364
13. Chiereghin A., et al. 2009. Monitoring of CMV T-cell immunity in patients receiving small bowel/multivisceral transplantation. OR 43, p. 73. In Abstr. XIth Int. Small Bowel Transplant Sympo., 9-12 September, Bologna, Italy.